$2.5M NIH Award to Develop a Multi-Modal Monitoring Solution for Myasthenia Gravis

BioSensics is pleased to announce a $2.5M/3-year award from the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH) to develop a robust multi-modal remote monitoring solution for myasthenia gravis (MG). The project involves two clinical studies to create and validate digital measures of MG symptoms: In the first clinical study, 20 individuals with MG will be monitored for 1 week. The second clinical study involves 50 participants who will be monitored for 12 months using the developed multi-modal remote monitoring solution. 

MG is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness and symptoms that interfere with activities of daily living and negatively impacts quality of life.  The remote monitoring solution includes 1) the use of  PAMSys for continuous remote monitoring of motor symptoms and function, and 2) development of a mobile software application to collect patient-reported information, speech data (to measure dysarthria) and face videos (to measure ptosis). One of the key goals of the study is to create standard ways for data capture at home and in the clinic in MG and other neurological disorders. 

The award is in collaboration with Dr. Amanda Guidon, MD, the Department of Neurology at Massachusetts General Hospital, and MGNet, NIH-funded Myasthenia Gravis Rare Disease Network. 

To learn more and discuss collaboration opportunities related to this project, as well as other BioSensics' projects , email info@biosensics.com. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.